Your browser doesn't support javascript.
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
Jalkanen, Pinja; Kolehmainen, Pekka; Häkkinen, Hanni K; Huttunen, Moona; Tähtinen, Paula A; Lundberg, Rickard; Maljanen, Sari; Reinholm, Arttu; Tauriainen, Sisko; Pakkanen, Sari H; Levonen, Iris; Nousiainen, Arttu; Miller, Taru; Välimaa, Hanna; Ivaska, Lauri; Pasternack, Arja; Naves, Rauno; Ritvos, Olli; Österlund, Pamela; Kuivanen, Suvi; Smura, Teemu; Hepojoki, Jussi; Vapalahti, Olli; Lempainen, Johanna; Kakkola, Laura; Kantele, Anu; Julkunen, Ilkka.
  • Jalkanen P; Institute of Biomedicine, University of Turku, Turku, Finland. pinja.r.jalkanen@utu.fi.
  • Kolehmainen P; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Häkkinen HK; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Huttunen M; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Tähtinen PA; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.
  • Lundberg R; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Maljanen S; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Reinholm A; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Tauriainen S; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Pakkanen SH; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Levonen I; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Nousiainen A; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Miller T; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Välimaa H; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Ivaska L; Department of Virology, University of Helsinki, Helsinki, Finland.
  • Pasternack A; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.
  • Naves R; Department of Physiology, University of Helsinki, Helsinki, Finland.
  • Ritvos O; Department of Physiology, University of Helsinki, Helsinki, Finland.
  • Österlund P; Department of Physiology, University of Helsinki, Helsinki, Finland.
  • Kuivanen S; Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Smura T; Department of Virology, University of Helsinki, Helsinki, Finland.
  • Hepojoki J; Department of Virology, University of Helsinki, Helsinki, Finland.
  • Vapalahti O; Department of Virology, University of Helsinki, Helsinki, Finland.
  • Lempainen J; Department of Virology, University of Helsinki, Helsinki, Finland.
  • Kakkola L; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Kantele A; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.
  • Julkunen I; Institute of Biomedicine, University of Turku, Turku, Finland.
Nat Commun ; 12(1): 3991, 2021 06 28.
Article in English | MEDLINE | ID: covidwho-1286457
ABSTRACT
As SARS-CoV-2 has been circulating for over a year, dozens of vaccine candidates are under development or in clinical use. The BNT162b2 mRNA COVID-19 vaccine induces spike protein-specific neutralizing antibodies associated with protective immunity. The emergence of the B.1.1.7 and B.1.351 variants has raised concerns of reduced vaccine efficacy and increased re-infection rates. Here we show, that after the second dose, the sera of BNT162b2-vaccinated health care workers (n = 180) effectively neutralize the SARS-CoV-2 variant with the D614G substitution and the B.1.1.7 variant, whereas the neutralization of the B.1.351 variant is five-fold reduced. Despite the reduction, 92% of the seronegative vaccinees have a neutralization titre of >20 for the B.1.351 variant indicating some protection. The vaccinees' neutralization titres exceeded those of recovered non-hospitalized COVID-19 patients. Our work provides evidence that the second dose of the BNT162b2 vaccine induces cross-neutralization of at least some of the circulating SARS-CoV-2 variants.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunogenicity, Vaccine / Broadly Neutralizing Antibodies / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-24285-4

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunogenicity, Vaccine / Broadly Neutralizing Antibodies / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-24285-4